Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Aus co has blockbuster plan

Posted 25 February 2021 AM

Melbourne-based Opthea is looking to get a foothold in the lucrative ophthalmology market by combining its investigational wet age-related macular degeneration treatment OPT-302 with either one of two blockbusters - Novartis' Lucentis or Bayer's Eylea.

These PBS-listed therapies are current standard-of-care treatments for wet AMD and DME and share the common mechanism of inhibiting VEGF-A.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas